Indicated for adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) — and for genotype 1 patients previously treated with a regimen containing an NS5A inhibitor or NS3/4A protease inhibitor, but not both.